EdgeRock Capital’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

EdgeRock Capital’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$412K	Sell	1,661 -39	-2%	-$8.4K	0.09%	82
2026 Q1	$341K	Sell	1,700 -78	-4%	-$16.1K	0.09%	87
2025 Q4	$367K	Buy	1,778 +650	+58%	+$130K	0.1%	88
2025 Q3	$202K	Sell	1,128 -116	-9%	-$19.8K	0.06%	118
2025 Q2	$201K	Sell	1,244 -503	-29%	-$80.1K	0.06%	109
2025 Q1	$297K	Sell	1,747 -875	-33%	-$152K	0.21%	52
2024 Q4	$436K	Buy	2,622 +1,058	+68%	+$181K	0.29%	46
2024 Q3	$269K	Buy	+1,564	New	+$259K	0.19%	58

Other funds holding FBT

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

BFG

Berger Financial Group Plymouth, Minnesota $1.96B AUM 20.58% 1-Year Est. Return

EdgeRock Capital's FBT Position: Q2 2026 in Review

EdgeRock Capital reduced its First Trust NYSE Arca Biotechnology Index Fund (FBT) stake by 2.3% in Q2 2026, selling an estimated $8.4K and leaving 1,661 shares worth $412K. The position accounts for 0.09% of the portfolio, ranked #82.

EdgeRock Capital first reported a position in FBT in Q3 2024 and has held it in 8 quarters since. The position peaked at $436K in Q4 2024. 339 funds tracked by Wall St. Rank hold FBT as of Q2 2026.

EdgeRock Capital held 1,661 shares of First Trust NYSE Arca Biotechnology Index Fund worth $412K as of Q2 2026.
EdgeRock Capital sold 39 First Trust NYSE Arca Biotechnology Index Fund shares in Q2 2026, an estimated $8.4K.
First Trust NYSE Arca Biotechnology Index Fund made up 0.09% of EdgeRock Capital's portfolio in Q2 2026, its #82 holding.
EdgeRock Capital first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q3 2024 and has held it in 8 quarters since.
EdgeRock Capital's First Trust NYSE Arca Biotechnology Index Fund position peaked at $436K in Q4 2024.
339 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q2 2026.

Based on EdgeRock Capital's 13F filing for Q2 2026, filed 24 Jul 2026.